MARKET

DRRX

DRRX

DURECT
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.270
+0.060
+4.96%
After Hours: 1.260 -0.01 -0.79% 19:51 09/21 EDT
OPEN
1.210
PREV CLOSE
1.210
HIGH
1.270
LOW
1.210
VOLUME
226.08K
TURNOVER
--
52 WEEK HIGH
2.947
52 WEEK LOW
1.200
MARKET CAP
288.92M
P/E (TTM)
-7.3030
1D
5D
1M
3M
1Y
5Y
DURECT Corporation Fireside Chat at Oppenheimer's Fall Healthcare Life Sciences & MedTech Summit
DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating...
PR Newswire · 6d ago
DURECT Corporation Fireside Chat at the H.C. Wainwright Annual Global Investment Conference
DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President, CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer and Dr. WeiQi Lin, Executive Vice President of R&D will be participating in a fir...
PR Newswire · 09/07 13:00
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
Would Shareholders Who Purchased DURECT's (NASDAQ:DRRX) Stock Year Be Happy With The Share price Today?
The simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make...
Simply Wall St. · 08/09 09:29
--Chardan Suspends Coverage on Durect at Buy Rating With $8 Price Target
MT Newswires · 08/02 11:19
Durect Files for Up to $250 Million Mixed-Securities Shelf
MT Newswires · 08/02 03:21
BRIEF-Durect Corp Files For Mixed Shelf Of Up To $250 Mln
reuters.com · 07/30 21:16
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DRRX. Analyze the recent business situations of DURECT through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DRRX stock price target is 6.50 with a high estimate of 7.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 151
Institutional Holdings: 146.27M
% Owned: 64.30%
Shares Outstanding: 227.50M
TypeInstitutionsShares
Increased
35
2.70M
New
11
1.52M
Decreased
41
5.42M
Sold Out
12
466.44K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.43%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Non-Executive Chairman/Independent Director
David Hoffmann
President/Chief Executive Officer/Director
James Brown
Chief Financial Officer/IR Contact Officer
Michael Arenberg
Senior Vice President
Judy Joice
Other
Norman Sussman
Director
Gail Farfel
Independent Director
Mohammad Azab
Independent Director
Simon Benito
Independent Director
Terrence Blaschke
Independent Director
Gail Maderis
Independent Director
Judith Robertson
No Data
  • All
  • Financials
  • Insiders
More
About DRRX
DURECT Corporation is a biopharmaceutical company focused on advancing lifesaving investigational therapies. The Company's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. DUR‑928 is a candidate in its Epigenetic Regulator Program. Injectable DUR-928 is under testing in a Phase II clinical trial and oral DUR-928 is under testing in a Phase I clinical trial. The chronic toxicity of DUR-928 was further assessed in a 6-month oral study in rats and in a 9-month oral study in dogs. POSIMIR enabling continuous sustained delivery of bupivacaine, a non-opioid local analgesic, over 3 days in adults to control post-surgical pain of patients.

Webull offers kinds of DURECT Corporation stock information, including NASDAQ:DRRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DRRX stock methods without spending real money on the virtual paper trading platform.